MCT1 and CD147 gene polymorphisms in Standardbred horses

Cost of transport, but not gluteus medius and red blood cells monocarboxylate-transporters density differentiated Brazilian Sport Horses at two performance levels

Cost of transport (COT) and monocarboxylate transporters (MCTs) could affect the ability to perform fast actions during a jumping discipline. This study aimed to compare the COT and evaluate the MCT1, MCT4, and their auxiliary protein CD147 content in the gluteus medius and RBCs of Brazilian sport horses (BH), a breed developed for jumping competitions, with low-level (LL) or intermediate-level (IL) jumping capacities. The physiological difference between the horses was assessed by an incremental jump test (IJT), in which the cost of lactate (COT_LAC) and heart rate (COT_HR) of running were determined for each animal by the ratio between each variable and the running speed. Western blotting was performed on muscle and RBC membranes to quantify MCT1, MCT4, and CD147. IL showed lower COT_LAC and COT_HR than LL at all jumping heights. The amount of MCT1, MCT4, and CD147 found in muscle and RBCs were not dependent on performance level. Muscle MCT4 and MCT1 were correlated positively with CD147. We conclude that the relatively small differences between performances did not relevantly influence MCT expression in BH. While MCT analyses are inaccessible for most trainers and veterinarians, the cost of transport measurements is a feasible and sensitive tool to distinguish intermediate and low-level jumping horses.

MCT1, MCT4 and CD147 gene polymorphisms in healthy horses and horses with myopathy

Polymorphisms in human lactate transporter proteins (monocarboxylate transporters; MCTs), especially the MCT1 isoform, can affect lactate transport activity and cause signs of exercise-induced myopathy. Muscles express MCT1, MCT4 and CD147, an ancillary protein, indispensable for the activity of MCT1 and MCT4. We sequenced the coding sequence (cDNA) of horse MCT4 for the first time and examined polymorphisms in the cDNA of MCT1, MCT4 and CD147 of 16 healthy horses. To study whether signs of myopathy are linked to the polymorphisms, biopsy samples were taken from 26 horses with exercise-induced recurrent myopathy. Two polymorphisms that cause a change in amino acid sequence were found in MCT1 (Val(432)Ile and Lys(457)Gln) and one in CD147 (Met(125)Val). All polymorphisms in MCT4 were silent. Mutations in MCT1 or CD147 in equine muscle were not associated with myopathy. In the future, a functional study design is needed to evaluate the physiological role of the polymorphisms found.

The horse genome derby: racing from map to whole genome sequence

The map of the horse genome has undergone unprecedented expansion during the past six years. Beginning from a modest collection of approximately 300 mapped markers scattered on the 31 pairs of autosomes and the X chromosome in 2001, today the horse genome is among the best-mapped in domestic animals. Presently, high-resolution linearly ordered gene maps are available for all autosomes as well as the X and the Y chromosome. The approximately 4350 mapped markers distributed over the approximately 2.68 Gbp long equine genome provide on average 1 marker every 620 kb. Among the most remarkable developments in equine genome analysis is the availability of the assembled sequence (EquCab2) of the female horse genome and the generation approximately 1.5 million single nucleotide polymorphisms (SNPs) from diverse breeds. This has triggered the creation of new tools and resources like the 60K SNP-chip and whole genome expression microarrays that hold promise to study the equine genome and transcriptome in ways not previously envisaged. As a result of these developments it is anticipated that, during coming years, the genetics underlying important monogenic traits will be analyzed with improved accuracy and speed. Of larger interest will be the prospects of dissecting the genetic component of various complex/multigenic traits that are of vital significance for equine health and welfare. The number of investigations recently initiated to study a multitude of such traits hold promise for improved diagnostics, prevention and therapeutic approaches for horses.

Potential applications of equine genomics in dissecting diseases and fertility

Following the recent development of high-resolution gene maps and generation of several basic tools and resources to use them in analyzing traits that are economically important to horse owners, genome analysis in horses is witnessing a shift towards developing an ability to analyze complex traits. The likelihood of this happening in the very near future is great, mainly because of the recent availability of the whole genome sequence in the horse. The latter has triggered the development of novel tools like SNP-chip and expression arrays that will permit rapid genome-wide analysis. While these tools will be used for a range of multi-factorial disease traits, attempts are underway to develop focused tools that can target reproduction, fertility and sex determination. For this, a catalog of sex and reproduction related (SRR) genes is being developed in horses. A recently developed dense map of the horse Y chromosome will provide genes that are expressed exclusively in males and, therefore, have an impact on stallion fertility. Overall, these advances in equine genome analysis hold promise for improved diagnosis and treatment of various conditions in horses.